■听力损失(HL)越来越被认为是一个重大的全球公共卫生问题。其与维生素D水平关系的研究也得到了广泛的关注。然而,血清生物标志物25-羟维生素D2(25(OH)D2)和D3(25(OH)D3)与不同类型HL之间的关联尚不清楚.本研究旨在探讨美国成年人血清25(OH)D2和25(OH)D3与HL的潜在关联。
■本研究分析了来自2015-2016年国家健康与营养检查(NHANES)的3,684名年龄在20-69岁之间的个体样本。HL被定义为在低频(500、1,000、2000Hz)下,任一耳朵的纯音平均值>25dB,语音频率(500,1,000,2000,4,000Hz),和高频(3,000,4,000,6,000,8,000Hz)。采用Logistic回归分析血清25(OH)D2和25(OH)D3与HL的关系。然后按年龄对研究人群进行分层,性别,种族,和教育水平分析不同亚组成年人之间的潜在差异。
■在多变量分析中,发现血清25(OH)D2与低频听力损失(LFHL)(OR:1.012[95%CI,1.005-1.020])和语音听力损失(SFHL)(OR:1.011[95%CI,1.003-1.018])独立相关.限制性三次样条分析显示血清25(OH)D2水平与LFHL之间存在线性剂量-反应关系(p表示线性<0.001),以及SFHL(线性p=0.001)。相反,在血清25(OH)D3水平与LFHL(非线性p=0.014)和SFHL(非线性p=0.025)之间观察到L形关联,阈值为35.3和36.5nmol/L,分别。较高的血清25(OH)D3水平与较低的高频听力损失(HFHL)概率相关(OR:0.994[95%CI,0.989-0.999])。阈值为53.9nmol/L。此外,通过亚组分析显示,糖尿病与LFHL患者血清25(OH)D2之间存在显著的交互作用(p=0.041).在非糖尿病人群中,血清25(OH)D2维持其与LFHL的相关性。
■我们的研究结果表明,在研究队列中,血清25(OH)D2浓度与LFHL和SFHL之间呈正相关。此外,血清25(OH)D3与LFHL和SFHL呈L型关系,和较高的血清25(OH)D3水平与较低的HFHL风险相关.
UNASSIGNED: Hearing loss (HL) is increasingly recognized as a significant global public health issue, and research on its relationship with vitamin D levels has gained wider attention. However, the association between serum biomarkers 25-hydroxyvitamin D2 (25(OH)D2) and D3 (25(OH)D3) with different types of HL remains unclear. This study aimed to investigate the potential association of serum 25(OH)D2 and 25(OH)D3 with HL in US adults.
UNASSIGNED: A sample of 3,684 individuals aged 20-69 years from the 2015-2016 National Health and Nutrition Examination (NHANES) was analyzed in this study. HL was defined as a pure tone average > 25 dB in either ear at low frequencies (500, 1,000, 2000 Hz), speech frequencies (500, 1,000, 2000, 4,000 Hz), and high frequencies (3,000, 4,000, 6,000, 8,000 Hz). Logistic regression was employed to examine the association between serum 25(OH)D2 and 25(OH)D3 and HL. The study population was then stratified by age, gender, race, and education level to analyze potential differences between adults in different subgroups.
UNASSIGNED: In the multivariate analysis, it was found that serum 25(OH)D2 was independently associated with low-frequency hearing loss (LFHL) (OR: 1.012 [95% CI, 1.005-1.020]) and speech-frequency hearing loss (SFHL) (OR: 1.011 [95% CI, 1.003-1.018]). Restrictive cubic spline analysis demonstrated a linear dose-response relationship between serum 25(OH)D2 levels and LFHL (p for linearity <0.001), as well as SFHL (p for linearity = 0.001). Conversely, an L-shaped association was observed between serum 25(OH)D3 levels and both LFHL (p for nonlinearity = 0.014) and SFHL (p for nonlinearity = 0.025), with threshold values identified at 35.3 and 36.5 nmol/L, respectively. Higher levels of serum 25(OH)D3 were associated with a lower probability of high-frequency hearing loss (HFHL) (OR: 0.994 [95% CI, 0.989-0.999]), with a threshold value identified at 53.9 nmol/L. Furthermore, a significant interaction between diabetes and serum 25(OH)D2 in LFHL was revealed through subgroup analysis (p = 0.041). In the non-diabetic population, serum 25(OH)D2 maintained its association with LFHL.
UNASSIGNED: Our findings suggested a positive association between serum 25(OH)D2 concentrations and both LFHL and SFHL in the studied cohort. Additionally, an L-shaped relationship was found between serum 25(OH)D3 and LFHL and SFHL, and higher levels of serum 25(OH)D3 were identified to be associated with a lower risk of HFHL.